DDInter1945 DDInter899
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Vorapaxar {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hemin
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Chamomile
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Vorapaxar may lead to a major life threatening interaction when taken with Anagrelide
Vorapaxar may lead to a major life threatening interaction when taken with Troleandomycin